How GLP-2 Is Stored and Handled: Stability Evidence and Its Limits

What the literature actually covers

Searches about storing GLP-2 usually mix two very different questions: how long a peptide survives inside the body, and how long it survives inside a container. The published, GLP-2-specific literature is heavily weighted towards the first. A human study reported that glucagon-like peptide-2 was degraded both in vitro and in vivo, with dipeptidyl-peptidase-4 identified as a principal route of cleavage (PMID 10946898), and medicinal-chemistry work described the creation of glepaglutide as the first long-acting GLP-2 analogue designed to enable a ready-to-use injection (PMID 39851172). Those two papers, together with a molecular-dynamics study of GLP-2 conformational behaviour (PMID 35808767), form most of the compound-specific stability picture available in the verified literature used here.

Everything else that people mean by "storage" — refrigerator versus freezer, expiry dating, what happens in a hot car — is addressed in the general pharmaceutical literature on lyophilized peptides and in manufacturer stability programmes, not in GLP-2 papers. This page flags which is which in every section, and deliberately avoids attaching numbers to claims that the cited papers do not contain.

Two meanings of "stability": metabolic versus pharmaceutical

Metabolic stability describes survival in plasma and tissue. The human degradation study reported that GLP-2 was cleaved in circulation, with DPP-4 activity central to its breakdown (PMID 10946898). The same enzyme axis appears elsewhere: a rodent cancer study reported that a DPP-4 inhibitor ameliorated 5-fluorouracil-induced intestinal mucositis, a model in which endogenous GLP-2 signalling is a proposed mediator (PMID 31664952). Protease sensitivity has also driven design work: researchers described computational design of potent and selective d-peptide agonists of the GLP-2 receptor, an approach whose rationale is resistance to proteolysis (PMID 37491005).

Pharmaceutical stability describes what happens in a vial: hydrolysis, deamidation, oxidation, aggregation and adsorption to container surfaces. None of those processes involve DPP-4. This is the single most common confusion in storage discussions — a short circulating half-life says nothing about how many months a sealed powder remains intact, and a long shelf life says nothing about how fast the peptide disappears once it reaches plasma.

Lyophilized versus reconstituted: what changes

Lyophilization (freeze-drying) removes the water that participates in most peptide degradation chemistry. This is general peptide formulation science rather than a GLP-2-specific finding: across peptide classes, dried solids typically show slower chemical change than aqueous solutions because hydrolysis and deamidation require water, and molecular mobility in a glassy solid is restricted. No study in the verified set measured the shelf life of lyophilized GLP-2 powder, so any specific figure quoted for it would be an extrapolation from other molecules.

The clearest compound-specific signal that liquid-state stability is difficult for this family comes from the glepaglutide programme, where researchers reported that the analogue was engineered so that a ready-to-use injection became possible rather than requiring reconstitution before administration (PMID 39851172). Solving the aqueous-stability problem was treated as a design objective in that work, which implies it was not a given for the native sequence. In routine clinical practice, the approved GLP-2 analogue teduglutide has been used in short bowel syndrome and described in observational reports of everyday treatment (PMID 30145039); the handling requirements of any licensed product are set by its own labelling and stability dossier, not by the clinical papers that describe its use.

Practical distinction drawn in the literature

• Dry solid: water content minimised; degradation pathways slowed but not eliminated. General peptide science, not GLP-2-specific.
• Aqueous solution: hydrolysis, deamidation and aggregation pathways become available; formulation chemists treat this as the harder problem, which is why a ready-to-use GLP-2 analogue was framed as an achievement (PMID 39851172).
• Encapsulated or carrier-bound: researchers reported GLP-2-loaded microspheres evaluated in a murine ulcerative colitis model (PMID 26218715) and an orally delivered stimulus-sensitive nanomedicine built to harness teduglutide in inflammatory bowel disease (PMID 39007246), both of which exist because unprotected peptide does not survive the intended environment.

Refrigeration: what is evidence and what is convention

Cold storage slows chemical reaction rates; that is physical chemistry rather than a GLP-2 finding. The verified literature contains no published study that compared refrigerated GLP-2 with room-temperature GLP-2 over time and measured potency loss, so this page does not assign a temperature or a duration to either state. Manufacturer-assigned storage conditions for licensed GLP-2 analogues are derived from formal stability testing of that specific formulation — including its buffer, excipients, stopper and container — and are not transferable to a different powder from a different source.

It is worth noting how much of stability depends on formulation rather than on the peptide alone. The microsphere and nanocarrier studies cited above (PMID 26218715, PMID 39007246) reported that the surrounding material, not the amino-acid sequence, determined whether the peptide reached its target intact.

Shelf life and expiry dating

Expiry dates on pharmaceutical peptides come from stability programmes run under standardised temperature and humidity conditions, with assays tracking purity, aggregation and degradation products over time. That is a regulatory process, not a published GLP-2 experiment. Research-grade material labelled for laboratory use carries no equivalent guarantee, and "research use only" labelling reflects that no regulator has reviewed its identity, purity or stability data.

Because the verified GLP-2 literature does not include a vial-stability dataset, three honest statements can be made: published degradation data for GLP-2 concern enzymatic cleavage in biological matrices (PMID 10946898); formulation-stability work in this family has been reported mainly through analogue engineering (PMID 39851172); and shelf-life numbers for any particular preparation come from its own certificate of analysis or labelling.

Room temperature and travel

Heat accelerates essentially all chemical degradation pathways, and excursions are usually described in terms of cumulative time-above-temperature rather than single events. Again, no GLP-2-specific thermal excursion study appears in the verified set. What the compound-specific literature does show is that GLP-2's conformation is sensitive to its physical environment: a simulation study reported that the conformational dynamics and secondary-structure content of GLP-2 changed under different applied electric field strengths (PMID 35808767). That work modelled electric fields, not luggage handling or airport scanners, and extending it to travel conditions would go beyond what the study examined.

The glepaglutide paper is the most directly relevant travel-adjacent evidence, because researchers described a ready-to-use injectable presentation as the practical goal of the redesign (PMID 39851172) — a reminder that convenience in handling is a property of a specific engineered formulation rather than of GLP-2 generally.

Freezing and freeze-thaw

In general peptide chemistry, freezing is used to slow degradation of stock solutions, while repeated freeze-thaw cycling is treated as a risk factor for aggregation and adsorption losses because of ice-interface stress, pH shifts in freezing buffers and concentration effects. The verified literature contains no freeze-thaw study of GLP-2, so no cycle count or temperature can be attributed to this compound. Lyophilization itself involves a freezing step, and the fact that GLP-2 analogues have been supplied as dried powders indicates the sequence tolerates that process under controlled conditions — an inference from product form, not a measured finding.

Signs of Degradation: What Studies Report

Visual inspection is limited. Analytical laboratories detect degradation with chromatography and mass spectrometry; the human degradation study identified cleaved GLP-2 fragments generated by DPP-4 activity using analytical methods rather than appearance (PMID 10946898). In other words, a solution can look unchanged while a substantial fraction of intact peptide has been converted to inactive or altered species.

What the broader peptide literature associates with visible change — cloudiness, particulates, discoloration, cake collapse or a powder that has turned sticky — reflects advanced physical change such as aggregation or moisture uptake. Those descriptors are general formulation science and are not GLP-2 findings. The functional consequence of degradation is loss of receptor-mediated activity: activity studies reported GLP-2 effects in C2C12 cells and mice in a muscle-aging model (PMID 38692155), suppression of LPS-induced inflammation in macrophages (PMID 25116357) and prevention of neuronal and glial changes in the distal colon of cisplatin-treated mice (PMID 33238628), all of which depend on intact peptide reaching the receptor.

Evidence map: compound-specific versus general

Context from physiology

GLP-2 is an endogenous peptide, and its regulation has been studied in human disease states: a clinical study reported patterns of glucagon-like peptide-1 and glucagon-like peptide-2 during human liver regeneration (PMID 37749369). Endogenous secretion and exogenous handling are different subjects, but the physiology explains why the molecule evolved to be short-lived rather than durable — and why protease-resistant analogues and d-peptide agonists were designed (PMID 37491005).

What remains unanswered

1. No published head-to-head comparison of refrigerated versus ambient GLP-2 powder over defined intervals appears in the verified literature.
2. No freeze-thaw or light-exposure study specific to GLP-2 appears in that set.
3. Stability data for analogues such as teduglutide and glepaglutide belong to those specific formulations; the glepaglutide work described a purpose-built ready-to-use presentation (PMID 39851172) rather than a general property of GLP-2 peptides.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question, and treat storage requirements for any specific product as a matter for that product's labelling and the professionals responsible for it.

References

• In vivo and in vitro degradation of glucagon-like peptide-2 in humans (The Journal of Clinical Endocrinology and Metabolism, 2000)
• Creating Glepaglutide, the First Long-Acting GLP-2 Analogue to Enable a Ready-to-Use Injection (Journal of Medicinal Chemistry, 2025)
• Conformational Dynamics of Glucagon-like Peptide-2 with Different Electric Field (Polymers, 2022)
• Computational Design of Potent and Selective d-Peptide Agonists of the Glucagon-like Peptide-2 Receptor (Journal of Medicinal Chemistry, 2023)
• Glucagon-like peptide-2-loaded microspheres as treatment for ulcerative colitis in the murine model (Journal of Microencapsulation, 2015)
• Orally Delivered Stimulus-Sensitive Nanomedicine to Harness Teduglutide Efficacy in Inflammatory Bowel Disease (Small, 2024)
• Experience with teduglutide treatment for short bowel syndrome in clinical practice (Clinical Nutrition, 2019)
• Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis (BMC Cancer, 2019)
• GLP-2 ameliorates D-galactose induced muscle aging by IGF-1/Pi3k/Akt/FoxO3a signaling pathway in C2C12 cells and mice (Archives of Gerontology and Geriatrics, 2024)
• GLP-2 suppresses LPS-induced inflammation in macrophages by inhibiting ERK phosphorylation and NF-κB activation (Cellular Physiology and Biochemistry, 2014)
• GLP-2 Prevents Neuronal and Glial Changes in the Distal Colon of Mice Chronically Treated with Cisplatin (International Journal of Molecular Sciences, 2020)
• Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration (Scientific Reports, 2023)